Gilead Sciences | GILD - Marktkapitalisierung

Aktienkurs
137.21
Täglich Wechseln
-3.90 -2.76%
Monatlich
-8.42%
Jährlich
28.14%
Q1 Prognose
133.09




Marktkapitalisierung Veränderung Datum
AbbVie USD 403.83B 5.2B 2025-12
Agios Pharmaceuticals USD 1.59B 745M 2025-12
ALKERMES USD 4.47B 146M 2026-03
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Biogen USD 25.82B 5.28B 2025-12
BioMarin Pharmaceutical USD 11.76B 348M 2026-03
Bristol-Myers Squibb USD 109.81B 18.01B 2025-12
Coherus Biosciences USD 183M 11M 2026-03
Eli Lilly USD 1.02T 293.84B 2025-12
Gilead Sciences USD 152.28B 14.55B 2025-12
GlaxoSmithKline GBP 74.36B 10.31B 2025-12
Glaxosmithkline GBP 107.89B 7.96B 2026-03
Incyte USD 19.39B 2.83B 2025-12
J&J USD 500.24B 67.44B 2025-12
Merck USD 261.26B 51.62B 2025-12
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novartis USD 240.48B 51.73B 2026-03
Pfizer USD 153.96B 12.4B 2026-03
PTC Therapeutics USD 6.1B 1.22B 2025-12
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Sanofi EUR 100.88B 4.46B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
United Therapeutics USD 20.98B 2.02B 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12